

Listing of the Claims

It is respectfully requested that the claims be amended without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows. This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A stabilized peptide formulation, either in a solution or in a suspension, consisting essentially of: (a) the peptide PACAP 66 or a salt thereof; (b) ZnCl₂ ~~a zinc salt~~; and (c) a pharmaceutically acceptable organic solvent, wherein said formulation is free of additional active components.
2. (Canceled)
3. (Previously presented) The formulation of claim 1, wherein the peptide PACAP 66 has an amino acid sequence as set forth in SEQ ID NO: 1.
4. – 7. (Canceled)
8. (Original) The formulation of claim 1, wherein said organic solvent is selected from the group consisting of DMSO, 1-methyl-2-pyrrolidinone, propanol, propylene glycol, glycerol acetate, monothioglycerol, acetic acid, diethanolamine, benzyl alcohol, ethyl lactate, glycerol formal, N-methylpyrrolidone, polyethyleneglycol 400, and isopropyl myristate.
9. (Canceled)
10. (Original) The formulation of claim 8, wherein said organic solvent is DMSO, 1-methyl-2-pyrrolidinone, or propanol.
11. (Canceled)
12. (Canceled)

13. (Canceled)
14. (Cancelled)
15. (Currently amended) The formulation of claim 1 ~~claim 11~~, wherein said ZnCl_2 is at a ZnCl_2 :peptide molar ratio of above 0.1 in said organic solvent.
16. (Currently amended) The formulation of claim 1 ~~claim 11~~, wherein said PACAP 66 and/or salts thereof are at a concentration of above 0.1 mg/mL of said organic solvent.
17. (Currently amended) A stabilized peptide formulation, consisting essentially of a dried mixture of an acid, the peptide PACAP 66 or a salt thereof, and a zinc salt, wherein said formulation is free of additional active components.
18. (Previously presented) The formulation of claim 17, wherein the peptide PACAP 66 has an amino acid sequence as set forth in SEQ ID NO: 1.
19. (Original) The formulation of claim 17, wherein said acid is an inorganic acid.
20. (Original) The formulation of claim 19, wherein said inorganic acid is selected from HCl and H_3PO_4 .
21. (Cancelled)
22. (Original) The formulation of claim 17, wherein said formulation is freeze-dried or spray-dried.
23. – 25. (Canceled)
26. (Currently amended) A stabilized peptide formulation, consisting essentially of a dried mixture of an inorganic acid, PACAP 66 (SEQ ID NO: 1) and/or a salt thereof, and a zinc salt, wherein said formulation is free of additional active components.
27. – 28. (Canceled)

29. (Previously presented) The formulation of claim 26, wherein said inorganic acid is selected from HCl and H₃PO₄.
30. (Original) The formulation of claim 26, wherein a molar ratio of said acid to said PACAP 66 and/or a salt thereof is above 0.1.
31. – 33. (Cancelled)
34. (Currently amended) A stabilized peptide formulation, consisting essentially of a dried mixture of ~~a zinc salt~~ ZnCl₂ and the peptide PACAP 66 or a salt thereof, wherein said formulation is free of additional active components.
35. (Original) The formulation of claim 34, further comprising a pharmaceutically acceptable organic solvent.
36. (Original) The formulation of claim 35, wherein said organic solvent is selected from the group consisting of DMSO, 1-methyl-2-pyrrolidinone, propanol, propylene glycol, glycerol acetate, monothioglycerol, acetic acid, diethanolamine, benzyl alcohol, ethyl lactate, glycerol formal, N-methylpyrrolidone, polyethyleneglycol 400, and isopropyl myristate.
37. (Original) The formulation of claim 36, wherein said organic solvent is DMSO, 1-methyl-2-pyrrolidinone or propanol.
38. – 39. (Canceled) .
40. (Previously presented) The formulation of claim 34, wherein the peptide PACAP 66 has an amino acid sequence as set forth in SEQ ID NO: 1.
41. – 43. (Canceled)
44. (Canceled)
45. (Canceled)

46. (Canceled)

47. (Cancelled)

48. (Canceled)

49. (Canceled)

50. (Canceled)

51. (Canceled)

52. – 67. (Cancelled)